Remes-Troche José María
Laboratorio de Fisiología Digestiva y Motilidad Gastrointestinal, Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Iturbide s/n entre Carmen Serdán y 20 de Noviembre, col. Centro, Veracruz, Veracruz, Mexico.
Dig Dis Sci. 2025 Apr;70(4):1283-1285. doi: 10.1007/s10620-025-08857-8. Epub 2025 Feb 19.
The potassium-competitive acid blockers (P-CABs) are a novel class of potent antisecretory drugs that unlike the proton pump inhibitors (PPIs) are not dependent on activated proton pumps, acting near maximally from the first dose, a pharmacokinetic advantage over PPIs. Tegoprazan, a novel P-CAB, offers potent and rapid acid suppression without delaying gastric emptying, distinguishing it from PPIs. This commentary contextualizes these results within the broader landscape of functional dyspepsia management, highlighting the potential benefits of tegoprazan in patients requiring antisecretory therapy, emphasizing the need for further research into its long-term impacts on motility, gut microbiota composition, and symptomatology. This analysis underscores how P-CABs may redefine antisecretory therapies.
钾离子竞争性酸阻滞剂（P-CABs）是一类新型强效抗分泌药物，与质子泵抑制剂（PPIs）不同，它们不依赖于激活的质子泵，从首剂起就能近乎最大程度地发挥作用，这是相对于PPIs的药代动力学优势。替戈拉赞是一种新型P-CAB，能强效快速抑制胃酸分泌且不延迟胃排空，这使其有别于PPIs。本述评将这些结果置于功能性消化不良管理的更广阔背景中，强调替戈拉赞在需要抗分泌治疗的患者中的潜在益处，强调有必要进一步研究其对动力、肠道微生物群组成和症状学的长期影响。该分析强调了P-CABs如何可能重新定义抗分泌治疗。
